Innophos recently signed an exclusive agreement with Japan-based Theravalues Corporation to distribute its ingredients in the United States.
Innophos Nutrition (North Salt Lake, UT) has signed an agreement to be the exclusive U.S. distributor of ingredients developed by Japan-based Theravalues Corporation (Tokyo). The agreement highlights two Theravalues ingredients in particular that will now be distributed by Innophos: Theracurmin and EMIQ.
“Innophos Nutrition will employ its sales, marketing, and distribution expertise and leverage the strength of its relationships with finished product manufacturers, to present and distribute Theracurmin and EMIQ, unique formulations shown through clinical studies to be ground-breaking nutritional ingredients,” says Innophos in a press release.
Theracurmin, a water-dispersible and heat and light stable curcumin powder, has been found to be 27 times more bioavailable than standard curcumin powder in studies, including 19 completed human clinical trials, says Innophos.
EMIQ, short for enzymatically-modified isoquercitrin, is a water-soluble polyphenol derived from rutin. Clinical studies have suggested EMIQ is 17 times more bioavailable than quercetin, may increase markers of body fat metabolism, and is a powerful antioxidant, according to Innophos.
“I am confident and enthusiastic that this strategic partnerhips with Innophos Nutrition will accelerate the expansion of these fantastic ingredients and consequently, improve health and wellness of people in the U.S.A.,” says Tadashi Hashimoto, representative director and president of Theravalues.
“Theravalues Corporation shares out commitment to innovation and high-quality products,” says Joseph Golowski, president, Innophos Nutrition. “We look forward to working together as we provide customers with access to these exciting ingredient.”